MedTrace Logo

Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma

NCT01604772 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2019-05-01

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well Akt inhibitor MK2206 works in treating patients with progressive, recurrent, or metastatic adenoid cyst carcinoma (cancer). Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Recurrent Oral Cavity Adenoid Cystic Carcinoma
  • Recurrent Salivary Gland Carcinoma
  • Salivary Gland Adenoid Cystic Carcinoma
  • Stage IVA Major Salivary Gland Cancer AJCC v7
  • Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7
  • Stage IVB Major Salivary Gland Cancer AJCC v7
  • Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7
  • Stage IVC Major Salivary Gland Cancer AJCC v7
  • Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7

Interventions

DRUG

Akt Inhibitor MK2206

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Alan Ho · Alliance for Clinical Trials in Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-23
Primary Completion
2013-10-24
Completion
2014-11-22

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01604772 on ClinicalTrials.gov